tiprankstipranks
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
US Market
ARWR
Arrowhead Pharmaceuticals
RESEARCH TOOLSreports

Arrowhead Pharmaceuticals (ARWR) Stock News & Sentiment

1,668 Followers
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
Premium
Ratings
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
14d ago
ARWR
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
Premium
Company Announcements
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
21d ago
8K
ARWR
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential
Premium
Company Announcements
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential
21d ago
ARWR
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
Premium
Company Announcements
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
2M ago
ARWR
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
Premium
Ratings
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
2M ago
ARWR
Is ARWR a Buy, Before Earnings?
Premium
Pre-Earnings
Is ARWR a Buy, Before Earnings?
2M ago
ARWR
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
Premium
Company Announcements
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
3M ago
8K
ARWR
More ARWR News >

ARWR News on the Web

H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks News
Bullish
Arrowhead Pharmaceuticals Stock Surges on Breakthrough Data
TipRanks News
Bullish
Arrowhead presents long-term efficacy, safety data for plozasiran
TipRanks News
Bullish
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (MAZE), Azitra Inc (AZTR) and Arrowhead Pharmaceuticals (ARWR)
TipRanks News
Bearish
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
TipRanks News
Neutral
Arrowhead price target lowered to $81 from $84 at BofA
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
ARWR
Sector Average
Media Buzz
This Week1 articles
Weekly Average3.5 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARWR’s Media Buzz Sentiment?
1 articles about ARWR were published this week. In an average week, 3.5 articles are published.
    What is ARWR’s weekly average amount of articles?
    In an average week, 3.5 articles about ARWR are published.
      What is ARWR’s News Sentiment?
      100% of articles about ARWR were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week